Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in Pulmonary Artery Pressure Following Initiation of Guideline-Directed Medical Therapies in Patients With Heart Failure: Insights From GUIDE-HF.

Circulation. Heart failure·2026
Same author

Admission Kidney Tubule Biomarkers Do Not Predict Acute Kidney Injury or In-Hospital Adverse Events in Acute Heart Failure.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Urine Tubular Biomarkers Are Associated With Natriuresis in Patients With Acute Heart Failure.

Journal of the American Heart Association·2025
Same author

Kidney Tubular Biomarkers Predict Risk of Death and Heart Failure Readmission in Acute Heart Failure.

Journal of the American Heart Association·2025
Same author

Racial differences in diuretic therapy, B-type natriuretic peptide values, and prognosis in acute heart failure.

Journal of cardiology·2025
Same author

Absence of Kidney Tubular Injury in Patients With Acute Heart Failure With Acute Kidney Injury.

Circulation. Heart failure·2024

Related Experiment Videos

Heart failure biomarkers.

Rajiv Choudhary1, Navaid Iqbal, Fatima Khusro

  • 1Department of Medicine, Capital Health Regional Medical Center-FULD, 750 Brunswick Avenue, Trenton, NJ 08638, USA. dr.rajivc@gmail.com

Journal of Cardiovascular Translational Research
|April 23, 2013
PubMed
Summary

Biomarker testing aids heart failure (HF) management by reflecting cellular events. Monitoring these biomarkers offers crucial insights for tailored treatment and improved patient outcomes.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Biochemistry

Background:

  • Biomarker testing in heart failure (HF) is increasingly utilized.
  • Biomarkers offer insights into pathophysiological processes at a cellular level.
  • They serve as valuable adjuncts in managing HF patients.

Purpose of the Study:

  • To review the diagnostic and prognostic capabilities of biomarkers in heart failure.
  • To explore the role of biomarkers in tailoring HF therapy.
  • To delineate the utility of specific biomarkers, alone or in combination, for improved accuracy.

Main Methods:

  • Literature review of widely studied biomarkers in the context of HF.
  • Analysis of research on the diagnostic and prognostic value of biomarkers.
  • Examination of studies focusing on biomarker-guided HF management.

Main Results:

  • Biomarkers reflect ongoing pathophysiological events in HF.
  • Monitoring biomarker levels provides incremental information on disease progression.
  • Specific biomarkers show potential for enhancing diagnostic accuracy.

Conclusions:

  • Biomarkers are essential tools for diagnosing and prognosing heart failure.
  • Biomarker monitoring facilitates personalized treatment titration in HF.
  • Continued research is vital for optimizing biomarker use in HF care.